Kew Olen M, Wright Peter F, Agol Vadim I, Delpeyroux Francis, Shimizu Hiroyuki, Nathanson Neal, Pallansch Mark A
WHO Global Specialized Reference Laboratory, Division of Viral and Rickettsial Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
Bull World Health Organ. 2004 Jan;82(1):16-23. Epub 2004 Feb 26.
Within the past 4 years, poliomyelitis outbreaks associated with circulating vaccine-derived polioviruses (cVDPVs) have occurred in Hispaniola (2000-01), the Philippines (2001), and Madagascar (2001-02). Retrospective studies have also detected the circulation of endemic cVDPV in Egypt (1988-93) and the likely localized spread of oral poliovirus vaccine (OPV)-derived virus in Belarus (1965-66). Gaps in OPV coverage and the previous eradication of the corresponding serotype of indigenous wild poliovirus were the critical risk factors for all cVDPV outbreaks. The cVDPV outbreaks were stopped by mass immunization campaigns using OPV. To increase sensitivity for detecting vaccine-derived polioviruses (VDPVs), in 2001 the Global Polio Laboratory Network implemented additional testing requirements for all poliovirus isolates under investigation. This approach quickly led to the recognition of the Philippines and Madagascar cVDPV outbreaks, but of no other current outbreaks. The potential risk of cVDPV emergence has increased dramatically in recent years as wild poliovirus circulation has ceased in most of the world. The risk appears highest for the type 2 OPV strain because of its greater tendency to spread to contacts. The emergence of cVDPVs underscores the critical importance of eliminating the last pockets of wild poliovirus circulation, maintaining universally high levels of polio vaccine coverage, stopping OPV use as soon as it is safely possible to do so, and continuing sensitive poliovirus surveillance into the foreseeable future. Particular attention must be given to areas where the risks for wild poliovirus circulation have been highest, and where the highest rates of polio vaccine coverage must be maintained to suppress cVDPV emergence.
在过去4年中,与疫苗衍生脊髓灰质炎病毒(cVDPV)传播相关的脊髓灰质炎疫情在伊斯帕尼奥拉岛(2000 - 2001年)、菲律宾(2001年)和马达加斯加(2001 - 2002年)爆发。回顾性研究还在埃及(1988 - 1993年)检测到地方性cVDPV的传播,并在白俄罗斯(1965 - 1966年)发现口服脊髓灰质炎疫苗(OPV)衍生病毒可能存在局部传播。OPV覆盖率的差距以及先前对相应血清型本土野生脊髓灰质炎病毒的根除是所有cVDPV疫情爆发的关键风险因素。通过使用OPV的大规模免疫运动,cVDPV疫情得以遏制。为提高检测疫苗衍生脊髓灰质炎病毒(VDPV)的敏感性,全球脊髓灰质炎实验室网络于2001年对所有正在调查的脊髓灰质炎病毒分离株实施了额外检测要求。这种方法很快促使人们认识到菲律宾和马达加斯加的cVDPV疫情,但未发现其他当前疫情。近年来,随着世界上大多数地区野生脊髓灰质炎病毒传播的停止,cVDPV出现的潜在风险急剧增加。由于2型OPV毒株更容易传播给接触者,其风险似乎最高。cVDPV的出现凸显了消除野生脊髓灰质炎病毒传播的最后据点、维持普遍高水平的脊髓灰质炎疫苗覆盖率、一旦安全可行就尽快停止使用OPV以及在可预见的未来持续进行敏感的脊髓灰质炎病毒监测的至关重要性。必须特别关注野生脊髓灰质炎病毒传播风险最高以及必须维持最高脊髓灰质炎疫苗覆盖率以抑制cVDPV出现的地区。